Bacterial therapies: completing the cancer treatment toolbox

Current Opinion in Biotechnology

Volumn 19, Issue 5, 2008, Pages 511-517

  St Jean, Adam T ^a   Zhang, Miaomin ^a   Forbes, Neil S ^a  

^a University of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOLOGY; BIOCHEMISTRY; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; MECHANISMS; MOLECULAR BIOLOGY; PATIENT TREATMENT;

ACTIVE BIOMOLECULES; CANCER THERAPIES; COMPLETE TREATMENT; CYTOTOXIN; ENZYMATIC ACTIVATION; INTERLEUKIN-2; PREFERRED GROWTH; TEMPORAL CONTROLS; TRANSPORT MECHANISMS; TUMOR TISSUES;

TUMORS;

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ARABINOSE; COMBRETASTATIN A4 PHOSPHATE; CYTOSINE DEAMINASE; CYTOTOXIN; FLUCYTOSINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; NITROREDUCTASE; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL STRAIN; CANCER THERAPY; DNA MODIFICATION; DRUG ACTIVITY; ENZYME ACTIVATION; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM;

BACTERIAL PHYSIOLOGICAL PHENOMENA; DRUG DELIVERY SYSTEMS; GENETIC ENHANCEMENT; HUMANS; NEOPLASMS; PROBIOTICS; PRODRUGS;

BACTERIA (MICROORGANISMS);

EID: 53049087992     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2008.08.004     Document Type: Review

References (67)

1. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4 (1998) 655-657
2. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58 (1998) 1408-1416
3. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S., and Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8 (2002) 878-884
4. Forbes N.S. Profile of a bacterial tumor killer. Nat Biotechnol 24 (2006) 1484-1485
5. Kasinskas R.W., and Forbes N.S. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67 (2007) 3201-3209. Using cylindroid models, the authors showed how chemotaxis worked in Salmonella to target different regions in tumors. Aspartate receptors initiate bacterial migration toward cylindroids, serine receptors launch penetration, and ribose/galactose receptors direct Salmonella into necrotic regions. This was a first attempt to explain the tumor targeting mechanism of motile anaerobes. New generic sites that can be engineered to improve tumor targeting efficacy were proposed as well.
6. Davis A.J., and Tannock J.F. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1 (2000) 86-93
7. Davis A.J., and Tannock I.F. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res 112 (2002) 1-26
8. Fidler I.J., Singh R.K., Yoneda J., Kumar R., Xu L., Dong Z., Bielenberg D.R., McCarty M., and Ellis L.M. Critical determinants of neoplastic angiogenesis. Cancer J Sci Am 6 (2000) S225-236
9. Fox M.E., Lemmon M.J., Mauchline M.L., Davis T.O., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther 3 (1996) 173-178
10. Lambin P., Theys J., Landuyt W., Rijken R., van der Kogel A., van der Schueren E., Hodgkiss R., Fowler J., Nuyts S., de Bruijn E., et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 4 (1998) 183-188
11. Nuyts S., Van Mellaert L., Theys J., Landuyt W., Lambin P., and Anne J. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs 13 (2002) 115-125
12. Theys J., Landuyt A.W., Nuyts S., Van Mellaert L., Lambin P., and Anne J. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev 25 (2001) 548-557
13. Minton N.P. Clostridia in cancer therapy. Nat Rev Microbiol 1 (2003) 237-242
14. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., Ash O., Carmichael E., Chakraborty A., Fischer J., et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 17 (1999) 37-41
15. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57 (1997) 4537-4544
16. Fujimori M., Amano J., and Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Dev 5 (2002) 200-203
17. Yazawa K., Fujimori M., Nakamura T., Sasaki T., Amano J., Kano Y., and Taniguchi S. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66 (2001) 165-170
18. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., Goebel R., and Szalay A.A. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22 (2004) 313-320
19. Nemunaitis J., Cunningham C., Senzer N., Kuhn J., Cramm J., Litz C., Cavagnolo R., Cahill A., Clairmont C., and Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10 (2003) 737-744
20. Toso J.F., Gill V.J., Hwu P., Marincola F.M., Restifo N.P., Schwartzentruber D.J., Sherry R.M., Topalian S.L., Yang J.C., Stock F., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20 (2002) 142-152
21. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., and Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 98 (2001) 15155-15160
22. Clairmont C., Lee K.C., Pike J., Ittensohn M., Low K.B., Pawelek J., Bermudes D., Brecher S.M., Margitich D., Turnier J., et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181 (2000) 1996-2002
23. Theys J., Pennington O., Dubois L., Anlezark G., Vaughan T., Mengesha A., Landuyt W., Anne J., Blurke P.J., Durre P., et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95 (2006) 1212-1219. Using a novel gene transfer technique, the authors demonstrated the capability to genetically engineer Clostridium strains. The technique was used to produce strains that have superior tumor colonization properties and overexpress nitroreductases for conversion of CB1954 for its toxic derivative.
24. Purdy D., O'Keeffe T.A., Elmore M., Herbert M., McLeod A., Bokori-Brown M., Ostrowski A., and Minton N.P. Conjugative transfer of clostridial shuttle vectors from Escherichia coli to Clostridium difficile through circumvention of the restriction barrier. Mol Microbiol 46 (2002) 439-452
25. Nakotte S., Schaffer S., Bohringer M., and Durre P. Electroporation of, plasmid isolation from and plasmid conservation in Clostridium acetobutylicum DSM 792. Appl Microbiol Biotechnol 50 (1998) 564-567
26. Stritzker J., Weibel S., Hill P.J., Oelschlaeger T.A., Goebel W., and Szalay A.A. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297 (2007) 151-162. Escherichia coli was demonstrated to have significant specialization in targeting tumor tissue over healthy tissues. Additionally, temporal control over protein delivery was shown in vivo by using l-arabinose inducible gene promoters.
27. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
28. Tredan O., Galmarini C.M., Patel K., and Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99 (2007) 1441-1454
29. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 6 (2006) 583-592
30. Graff C.P., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63 (2003) 1288-1296
31. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., Brown E.B., Izumi Y., Campbell R.B., Berk D.A., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 98 (2001) 4628-4633
32. Kasinskas R.W., and Forbes N.S. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94 (2006) 710-721
33. Zhao M., Yang M., Li X.M., Jiang P., Baranov E., Li S., Xu M., Penman S., and Hoffman R.M. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A 102 (2005) 755-760
34. Zhao M., Yang M., Ma H., Li X., Tan X., Li S., Yang Z., and Hoffman R.M. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66 (2006) 7647-7652
35. Zhao M., Geller J., Ma H., Yang M., Penman S., and Hoffman R.M. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A 104 (2007) 10170-10174. A Leu/Arg auxotrophic mutant of S. typhimurium A1-R was demonstrated effective as a mono therapy of metastatic PC-3 human prostate tumor on mice. The auxotrophy limits growth in healthy tissues while allowing for proliferation in all tumor regions.
36. Wei M.Q., Mengesha A., Good D., and Anne J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 259 (2008) 16-27
37. Forbes N.S., Munn L.L., Fukumura D., and Jain R.K. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63 (2003) 5188-5193
38. Mei S., Theys J., Landuyt W., Anne J., and Lambin P. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium. Anticancer Res 22 (2002) 3261-3266
39. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 9 (2002) 291-296
40. Westphal K., Leschner S., Jablonska J., Loessner H., and Weiss S. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 68 (2008) 2952-2960
41. Lee C.H., Wu C.L., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 12 (2005) 175-184
42. Lee C.H., Wu C.L., Tai Y.S., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol Ther 11 (2005) 707-716
43. + T cells increased, and cell death within the tumor environment was induced.
44. Weibel S., Stritzker J., Eck M., Goebel W., and Szalay A.A. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 10 6 (2008) 1235-1248
45. Möse J.R., and Möse G. Oncogenesis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 24 (1964) 212-216
46. Malmgren R.A., and Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumor following intravenous spore administration. Cancer Res 15 (1955) 473-478
47. Parker R.C., Plummer H.C., Siebenmann C.O., and Chapman M.G. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med 66 (1947) 461-467
48. Thiele E.H., Arison R.N., and Boxer G.E. Oncogenesis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 24 (1964) 222-233
49. Carey R.W., Holland J.F., Whang H.Y., Neter E., and Bryant B. Clostridial oncolysis in man. Eur J Cancer 3 (1967) 37-46
50. Dang L.H., Bettegowda H., Agrawal N., Cheong I., Huso D., Fil P., Loganzos F., Greenbergell L., Barkoczy J., Pettit G.R., et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 3 (2004) 326-337
51. Bettegowda C., Dang L.H., Abrams R., Huso D.L., Dillehay L., Cheong I., Agrawal N., Borzillary S., McCaffery J.M., Watson E.L., et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 100 (2003) 15083-15088
52. Bettegowda C., Huang X., Lin J., Cheong I., Kohli M., Szabo S.A., Zhang X., Diaz L.A., Velculescu Ve, Parmigiani G., et al. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotech 24 (2006) 1573-1580
53. Theys J., Landuyt W., Nuyts S., Van Mellaert L., van Oosterom A., Lambin P., and Anne J. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 8 (2001) 294-297
54. Nuyts S., Theys J., Landuyt W., van Mellaert L., Lambin P., and Anne J. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res 21 (2001) 857-861
55. Nuyts S., Van Mellaert L., Barbe S., Lammertyn E., Theys J., Landuyt W., Bosmans E., Lambin P., and Anne J. Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl Environ Microbiol 67 (2001) 4464-4470
56. Nuyts S., Van Mellaert L., Theys J., Landuyt W., Bosmans E., Anne J., and Lambin P. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther 8 (2001) 1197-1201
57. Dresselaers T., Theys J., Nuyts S., Wouters B., de Bruijn E., Anne J., Lambin P., Van Hecke P., and Landuyt W. Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br J Cancer 89 (2003) 1796-1801
58. Dubois L., Dresselaers T., Landuyt W., Paesmans K., Mengesha A., Wouters B.G., Van Hecke P., Theys J., and Lambin P. Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression. Br J Cancer 96 (2007) 758-761
59. Barbe S., Van Mellaert L., Theys J., Geukens N., Lammertyn E., Lambin P., and Anne J. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 246 (2005) 67-73
60. Parmiani G., Rivoltini L., Andreola G., and Carrabba M. Cytokines in cancer therapy. Immunol Lett 74 (2000) 41-44
61. Semenza G.L. HIF-1, O-2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107 (2001) 1-3
62. Groot A.J., Mengesha A., van der Wall E., van Diest P.J., Theys J., and Vooijs M. Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 364 (2007) 985-989
63. Palffy R., Gardlik R., Hodosy J., Behuliak M., Resko P., Radvansky J., and Celec P. Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 13 (2006) 101-105
64. Vassaux G., Nitcheu J., Jezzard S., and Lemoine N.R. Bacterial gene therapy strategies. J Pathol 208 (2006) 290-298
65. Weiss S., and Chakraborty T. Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr Opin Biotechnol 12 (2001) 467-472
66. Yuhua L., Kunyuan G., Hui C., Yongmei X., Chaoyang S., Xun T., and Daming R. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer 94 (2001) 438-443
67. Lee C.H., Wu C.L., and Shiau A.L. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 6 (2004) 1382-1393